X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
QRX003 is a topical lotion formulated with Invisicare®, a proprietary delivery technology, and contains a broad-spectrum serine protease inhibitor. It is being developed for the treatment of netherton syndrome.
Lead Product(s): QRX003
Therapeutic Area: Rare Diseases and Disorders Product Name: QRX003
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
QRX003 is a topical lotion, formulated with a proprietary delivery technology, and contains a broad-spectrum serine protease inhibitor. It is being evaluated for the treatment of netherton syndrome.
Lead Product(s): QRX003
Therapeutic Area: Rare Diseases and Disorders Product Name: QRX003
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
QRX003 is a once-daily topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary invisicare® delivery technology. It is being investigated for treating netherton syndrome.
Lead Product(s): QRX003
Therapeutic Area: Genetic Disease Product Name: QRX003
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
QRX003 is a once-daily topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary invisicare® delivery technology. It is being investigated for treating netherton syndrome.
Lead Product(s): QRX003
Therapeutic Area: Genetic Disease Product Name: QRX003
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
QRX003 is a once-daily topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary invisicare® delivery technology. It is being investigated for treating netherton syndrome.
Lead Product(s): QRX003
Therapeutic Area: Genetic Disease Product Name: QRX003
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
The active ingredient in QRX003 is a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to down-regulate the hyperactivity of skin kallikreins, leading to a more normalized rate of skin shedding.
Lead Product(s): QRX003
Therapeutic Area: Rare Diseases and Disorders Product Name: QRX003
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
The active ingredient in QRX003 is a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to down-regulate the hyperactivity of skin kallikreins, leading to a more normalized rate of skin shedding.
Lead Product(s): QRX003
Therapeutic Area: Rare Diseases and Disorders Product Name: QRX003
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
QRX003 is Quoin’s lead product candidate and has the potential to become the first approved treatment for Netherton Syndrome. Quoin intends to self-commercialize QRX003, and its other product candidates, in the US and Europe.
Lead Product(s): QRX003
Therapeutic Area: Genetic Disease Product Name: QRX003
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
The active ingredient in QRX003 is a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to down-regulate the hyperactivity of skin kallikreins leading to a more normalized rate of skin shedding.
Lead Product(s): QRX003
Therapeutic Area: Rare Diseases and Disorders Product Name: QRX003
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
QRX003 is Quoin's lead product for Netherton syndrome. Netherton syndrome, a form of ichthyosis, is a rare hereditary skin disorder caused by mutation in SPINK5 gene (serine protease inhibitor, Kazal Type 5) that leads to severe skin barrier defects and recurring infections.
Lead Product(s): QRX003
Therapeutic Area: Rare Diseases and Disorders Product Name: QRX003
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endo Ventures Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
